The Decode Scleroderma Study
72 people have signed up for this new trial for people living with diffuse scleroderma and now this clinical study, to test a new investigational drug for use in Diffuse Scleroderma, is ready to start.
Diffuse Scleroderma is a chronic and life limiting condition for which there is currently no cure. Treatment is based on the management of symptoms and the prevention of further complications
There is an urgent unmet need to better support people living with diffuse scleroderma through more effective treatments. The DECODE Scleroderma Study is testing an investigational study drug to see if it is effective in reducing the symptoms and severity of Diffuse Scleroderma.
Can I take part?
The study is now full and they are not accepting new participants.
About the DECODE Scleroderma Study:
The DECODE Scleroderma Study is trying to determine whether an investigational study drug reduces symptoms and severity of diffuse scleroderma.
The investigational study drug is being compared with a placebo – a substance that looks similar to the study drug but contains no active medication.
Participants are chosen randomly by computer as to whether they receive the investigational study drug or the placebo.
What is Involved?
Participants are involved for approximately 60 weeks which includes screening, treatment and follow-up.
The study drug will be administered orally once daily, in the morning, with or without food. They will also continue with their current treatments for Diffuse Scleroderma.
Participation includes attending up to nine study visits.
Throughout the study, staff will monitor their health. The site will also perform physical examinations and collect blood and urine samples for laboratory testing. Over the course of the study, participants will be asked to complete study-related questionnaires.
Who will be joining the study?
The DECODE Scleroderma Study will include about 50 research sites in eight countries - UK, Belgium, Germany, Spain, Italy, Poland US, and Canada. There are 72 adults with diffuse scleroderma taking part in the study across those countries
You can find out more about the study here
How are SRUK involved?
We are helping to promote the study in the UK as we believe it is of interest, and could be of benefit, to the scleroderma community.
Will you keep us updated with how the study is progressing?
Yes, whenever there is any news we will share that with our community.